The history of psychedelics is older than most religions, older than written language, and — depending on which cave painting you trust — possibly older than agriculture itself. That matters. If you're reading this because you're weighing a ceremony or a retreat, it helps to know that ayahuasca, peyote, psilocybin, and the rest aren't a wellness trend invented last Tuesday. They're part of a long, messy, beautifully human story about people trying to understand consciousness, heal sickness, and reckon with what some traditions call the master plants.

This is a tour through that story. We'll move from prehistoric murals to Spanish conquistadors, from a Swiss chemist's bicycle ride to the modern psychedelic research labs at Johns Hopkins. Along the way, I'll point out where the trail goes cold, where the science gets interesting, and what it all means for someone considering plant medicine for addiction, depression, or the slower kind of stuck that doesn't have a name yet.

Ancient Roots: The Oldest Evidence of Psychedelic Use

The deepest archaeological trail leads to a cave in the Tassili-N-Ajjer plateau in the Algerian Sahara. Painted on its rock walls, somewhere between 7,000 and 9,000 years old, is a figure researchers nicknamed the “mushroom shaman” — a bee-headed character with mushrooms growing out of his body. Scholars believe the species depicted is Psilocybe mairei, a psychedelic mushroom native to North Africa. Take a moment with that. People were painting their visions on cave walls before anyone built a pyramid.

Across the Atlantic, the evidence is just as old. In the Rio Grande region of what's now Texas, peyote specimens dating back to roughly 3,700 BC have been analysed for mescaline content. The conclusion was straightforward: Indigenous North Americans recognised the psychoactive properties of peyote at least 5,700 years ago. In northern Peru, a stone carving from around 1,300 BC shows a deity clutching a San Pedro cactus — another mescaline-bearing plant still used in ceremony today.

Further south, in Mexico and Guatemala, archaeologists have unearthed carved “mushroom stones” dated between 1,000 and 1,500 BC, widely interpreted as ritual objects connected to psilocybin use. And in 2019, researchers described a 1,000-year-old shaman's pouch found in southwestern Bolivia, containing snuffing tablets, a snuffing tube, and chemical residues of bufotenin, DMT, and harmine. That last combination is significant — harmine plus DMT is the basic pharmacology of ayahuasca. Whether the brew itself is that old, we can't quite prove. But the molecules were in the right pouch.

Western Discovery: Conquest, Curiosity, and the First Written Accounts

Europe didn't go looking for psychedelics. They stumbled into them, usually while trying to convert or conquer the people who already had a relationship with these plants. The earliest written record comes from 1496, when Friar Ramon Pane — travelling with Columbus on his second voyage — described how the Taino of the Caribbean used a snuff called cohoba, made from a DMT-containing shrub. He didn't approve. He documented it anyway.

Sixty-odd years later, the Spanish missionary Bernardino de Sahagún catalogued Aztec use of peyote and psilocybin mushrooms in his Florentine Codex. In the 1570s, the conquistador-physician Francisco Hernández recorded the Aztec use of ololiuqui, the seeds of a morning glory species containing LSA — a close chemical cousin to LSD. The Aztecs had their own pharmacology, fully developed, and the Spanish chroniclers preserved it, often while condemning it.

It took until 1851 for ayahuasca to enter the Western written record. The English botanist Richard Spruce, exploring the upper Amazon, watched the Tukano people drink the brew and — to his credit — tried it himself. Thirteen years later, the French physician Griffon du Bellay reported iboga use in Gabon and the Congo, describing the root that would, more than a century later, become central to a particular kind of addiction recovery work.

The Early Science: When Westerners Started Self-Experimenting

Some of the early Western encounters with psychedelics were intentional. Others were, let's say, agricultural accidents. In 1799 in London, a man went out to pick mushrooms for his family's breakfast and brought home a fistful of Psilocybe semilanceata by mistake. The whole family had what is almost certainly the first medically documented psilocybin experience in Britain. Their doctor was, by all accounts, baffled.

From there, things turned more deliberate. In 1887 a Texas physician named J.R. Briggs published an account of his own peyote self-experiment. In 1893, the Comanche chief Quanah Parker handed over 50 pounds of dried peyote buttons to a Smithsonian ethnologist, and some of that material ended up in the hands of the philosopher William James. In 1897, the German pharmacologist Arthur Heffter isolated mescaline and swallowed 150 milligrams of it — the first known human experience with a purified psychedelic compound. He took careful notes, which was very on-brand for a nineteenth-century chemist.

Then came 1943. Albert Hofmann, a Swiss chemist at Sandoz Laboratories, accidentally absorbed a trace of a compound he'd synthesized five years earlier and called LSD-25. A few days later, on April 19th, he ingested 250 micrograms on purpose, hopped on his bicycle to ride home, and changed the trajectory of twentieth-century neuroscience. That bike ride still gets celebrated as Bicycle Day. The man lived to 102, which is either a coincidence or a hell of an endorsement.

Prohibition and the Long Quiet

The 1950s and early 60s were a strange, productive window. Researchers ran more than a thousand clinical studies on LSD, exploring its potential for alcoholism, depression, end-of-life anxiety, and what we'd now call PTSD. Psilocybin was synthesised by Hofmann in 1958 and quickly entered psychiatric research. For a moment it looked like Western medicine might genuinely fold these compounds into its toolkit.

Then the culture turned. The compounds escaped the lab, became woven into the counterculture, and by 1970 the U.S. Controlled Substances Act had placed LSD, psilocybin, mescaline, and DMT into Schedule I — meaning, officially, no medical use and high abuse potential. Most of the world followed. Research funding evaporated. Several promising therapeutic threads simply got cut, mid-experiment. A handful of underground therapists kept working quietly. Almost everyone else moved on.

This is the part of the story that's worth pausing on if you're considering plant medicine today. The reason your doctor probably can't prescribe psilocybin for your depression isn't that the science failed. It's that the science was halted, politically, for roughly forty years. We are still catching up.

The Psychedelic Renaissance: Where Things Stand Now

Somewhere around the late 1990s, the door cracked open again. Roland Griffiths' team at Johns Hopkins published carefully designed psilocybin studies showing durable reductions in depression and end-of-life distress. MAPS pushed MDMA-assisted therapy for PTSD through phase 3 trials. Imperial College London opened a dedicated Centre for Psychedelic Research. Ibogaine clinics opened in Mexico, working specifically with opioid and stimulant addiction. Ayahuasca retreats — once a rumour passed between travellers in Cusco hostels — became something a software engineer in Berlin might book on her phone.

The research now points in directions that would have made Hofmann nod. Psilocybin shows real promise for treatment-resistant depression. Ibogaine appears, in observational studies, to interrupt opioid cravings in a way nothing else does. Ayahuasca has been studied for its effects on the default mode network — the brain circuitry associated with rumination and rigid self-narrative. The mechanism isn't magic. It looks more like a temporary loosening of mental ruts, with a window afterward where new patterns can take hold. That window is what serious facilitators call integration, and it's where the real work happens.

A few practical things worth knowing if you're considering a retreat:

• Legality varies wildly. Ayahuasca is legal in Peru, Brazil, Costa Rica, and a few other jurisdictions. Ibogaine treatment is legal in Mexico, Costa Rica, and New Zealand. Psilocybin retreats operate openly in Jamaica and the Netherlands. The U.S. is a patchwork — Oregon and Colorado have their own frameworks; federal law still says no.
• Screening matters. Reputable retreats ask about your medications (SSRIs and MAOIs are the big ones), cardiac history, and mental health background. If a retreat doesn't screen, that's a flag.
• Integration is half the medicine. The ceremony is dramatic. The weeks after, when you're trying to bring insights into a job, a marriage, a body — that's where lives actually change.
• Cost is real. A week-long ayahuasca retreat runs anywhere from $1,200 to $4,000 or more. Ibogaine treatment is typically $5,000 to $10,000 because of the medical monitoring involved. Cheaper isn't always worse, but suspiciously cheap usually is.

Why the History Matters to a Reader Considering a Retreat

Here's the honest version. The plants and compounds we now call psychedelics have been part of human life for thousands of years, used by people who took the work seriously and built elaborate frameworks around it. The West discovered them late, studied them briefly, banned them in a panic, and is now slowly, awkwardly remembering what older cultures already knew. The current renaissance isn't a discovery. It's a homecoming with paperwork.

If you're considering plant medicine for addiction, trauma, or that quiet kind of depression that doesn't make a scene but rearranges your whole life — you're stepping into a tradition with deep roots, not a wellness fad. Knowing the history doesn't tell you whether a retreat is right for you. It does tell you that the question deserves more than a weekend's research. Talk to people who've done it. Read about the specific medicine you're drawn to. Find facilitators who can describe their lineage and their screening process in plain language.

If something here speaks to you, the ayahuasca, psilocybin, and ibogaine retreats discussed across the broader plant-medicine world can be browsed on our marketplace here. Take your time. These plants have waited 9,000 years; they'll wait a few more weeks while you choose well.